Skip to content

Construction and application of ASCVD risk prediction model for type 2 diabetes patients with nonalcoholic fatty liver disease based on MMC platform

Construction and application of ASCVD risk prediction model for type 2 diabetes patients with nonalcoholic fatty liver disease based on MMC platform

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076366
Enrollment
Unknown
Registered
2023-10-07
Start date
2023-10-09
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

Interventions

T2DM with NAFLD without ASCVD group:None
T2DM with NAFLD with ASCVD group:None

Sponsors

Xuzhou first People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1: T2DM meets the WHO diabetes diagnosis and classification standard in1999 2: NAFLD meets the diagnostic criteria of the fatty liver and alcoholic liver disease group of the hepatology branch of the Chinese Medical Association and the fatty liver disease expert committee of the Chinese Medical Association in the guidelines for the prevention and treatment of non-alcoholic fatty liver disease (2018 update)

Exclusion criteria

Exclusion criteria: 1: Type 1 diabetes 2: Severe liver damage or renal insufficiency 3: Patients with alcohol and / or drug abuse 4: Alcoholic fatty liver disease, various viral hepatitis 5: Acute complications of diabetes 6: Infectious diseases 7: Hemopathy 8: Rheumatism 9: Malignant tumor 10: Recent surgery and trauma 11: Serious heart disease 12. Glycated hemoglobin (HbA1c) > 9.0%

Design outcomes

Primary

MeasureTime frame
body mass index;Fasting blood glucose;High density lipoprotein cholesterol;Low density lipoprotein cholesterol;?- Glutamyl transpeptidase;Glycosylated hemoglobin A1c;Glutamic oxaloacetic transaminase;Glutamic pyruvic transaminase;Color Doppler ultrasound of liver;Total cholesterol;Triglyceride;Visceral Fat Area;Ankle Brachial Index; Pulse Wave Velocity;Homeostasis model assessment of insulin resistance(HOMA-IR);

Secondary

MeasureTime frame
Creatinine;

Countries

China

Contacts

Public ContactHuo Yan

Xuzhou first People's Hospital

huoyan2640@163.com+86 158 9523 1170

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026